CoreCap Advisors
LGND icon

CoreCap Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

CoreCap Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$188K Buy
603
+175
+41% +$51.7K 0.01% 861
2026
Q2 		$135K Buy
428
+425
+14,167% +$100K ﹤0.01% 1002
2026
Q1 		$599 Hold
3
– – ﹤0.01% 2624
2025
Q4 		$567 Buy
+3
New +$576 ﹤0.01% 2686

Other funds holding LGND

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Pembroke Management
Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Woodstock Corp
Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return
Isthmus Partners
Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return
Moody National Bank Trust Division
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

CoreCap Advisors's LGND Position: Q3 2026 in Review

CoreCap Advisors increased its Ligand Pharmaceuticals (LGND) stake by 41% in Q3 2026, buying an estimated $51.7K and bringing the position to 603 shares worth $188K. The position accounts for 0.01% of the portfolio, ranked #861.

CoreCap Advisors first reported a position in LGND in Q4 2025 and has held it in 4 quarters since. 74 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • CoreCap Advisors held 603 shares of Ligand Pharmaceuticals worth $188K as of Q3 2026.
  • CoreCap Advisors bought 175 Ligand Pharmaceuticals shares in Q3 2026, an estimated $51.7K.
  • Ligand Pharmaceuticals made up 0.01% of CoreCap Advisors's portfolio in Q3 2026, its #861 holding.
  • CoreCap Advisors first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 74 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.